Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

Author： Qiu Y.   Bhattacharjee S.   Kraft P.   John T.M.   Craig E.   Haynes-Johnson D.   Guan J.   Jiang W.   Macielag M.   Sui Z.   Clancy J.   Lundeen S.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.472, Iss.1, 2003-07, pp. : 73-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer   Bivalacqua Trinity J   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite

Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor

By Sommer Frank  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, Iss. 2, 2005-08 ,pp. : 295-301

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review

By  

Current Drug Abuse Reviews, Vol. 4, Iss. 2, 2011-06 ,pp. : 87-94

Bentham Science Publishers

Access to resources Recommend Favorite

T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats

By Inoue H.   Yano K.   Ikeo T.   Noto T.   Kikkawa K.  

European Journal of Pharmacology, Vol. 422, Iss. 1, 2001-06 ,pp. : 109-114

Elsevier

Access to resources Recommend Favorite

Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum

By Takagi M.   Mochida H.   Noto T.   Yano K.   Inoue H.   Ikeo T.   Kikkawa K.  

European Journal of Pharmacology, Vol. 411, Iss. 1, 2001-05 ,pp. : 161-168

Elsevier

Access to resources Recommend Favorite